Immunotherapies are changing the landscape of advanced solid tumor treatment. These therapies have different mechanisms of action and include oncolytic viruses, checkpoint inhibitors, such as CTLA-4 or PD1/PD-L1 monoclonal antibodies, and CSF-1R antibodies. Given the growing therapeutic impact of these agents in oncology, it is important to better understand their properties. Immunotherapies generate new toxicity profiles that are called immune-related adverse events and require specific management. This review focuses on the mechanisms of action of such side effects, as well as their description and their general management.

中文翻译：

---

免疫疗法的毒性

免疫疗法正在改变晚期实体瘤治疗的前景。这些疗法具有不同的作用机制，包括溶瘤病毒，检查点抑制剂（例如CTLA-4或PD1 / PD-L1单克隆抗体）和CSF-1R抗体。鉴于这些药物在肿瘤治疗中的作用越来越大，因此重要的是更好地了解其性质。免疫疗法会产生新的毒性反应，称为免疫相关不良事件，需要进行特殊处理。这篇综述着重于这种副作用的作用机制，以及它们的描述和总体管理。